HUP0101268A2 - A női nemi diszfunkció kezelésére alkalmas gyógyszerkészítmények - Google Patents

A női nemi diszfunkció kezelésére alkalmas gyógyszerkészítmények

Info

Publication number
HUP0101268A2
HUP0101268A2 HU0101268A HUP0101268A HUP0101268A2 HU P0101268 A2 HUP0101268 A2 HU P0101268A2 HU 0101268 A HU0101268 A HU 0101268A HU P0101268 A HUP0101268 A HU P0101268A HU P0101268 A2 HUP0101268 A2 HU P0101268A2
Authority
HU
Hungary
Prior art keywords
female sexual
pharmaceutical compositions
sexual dysfunction
treating female
apomorphine
Prior art date
Application number
HU0101268A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals, Inc. filed Critical Pentech Pharmaceuticals, Inc.
Publication of HUP0101268A2 publication Critical patent/HUP0101268A2/hu
Publication of HUP0101268A3 publication Critical patent/HUP0101268A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya a női szexuális díszfunkció kezelésére alkalmasszublingvális adagolási formájú gyógyszerkészítmény, amelyhatóanyagként apomorfint tartalmaz. A gyógyszerkészítmény előnyösadagolási formái az apomorfin mellett kiegészítőleg béta-ciklodextrintis tartalmaznak. Ó
HU0101268A 1998-01-30 1999-01-28 Pharmaceutical compositions for treating female sexual dysfunction HUP0101268A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction
PCT/US1999/001776 WO1999038467A1 (en) 1998-01-30 1999-01-28 Treatment of female sexual dysfunction

Publications (2)

Publication Number Publication Date
HUP0101268A2 true HUP0101268A2 (hu) 2001-09-28
HUP0101268A3 HUP0101268A3 (en) 2002-12-28

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101268A HUP0101268A3 (en) 1998-01-30 1999-01-28 Pharmaceutical compositions for treating female sexual dysfunction

Country Status (34)

Country Link
US (2) US5945117A (hu)
EP (1) EP1056419A4 (hu)
JP (1) JP2002501875A (hu)
KR (1) KR20010040477A (hu)
CN (1) CN1250221C (hu)
AR (1) AR017976A1 (hu)
AU (1) AU752928B2 (hu)
BG (1) BG64667B1 (hu)
BR (1) BR9908038A (hu)
CA (1) CA2322289A1 (hu)
CO (1) CO4970819A1 (hu)
CR (1) CR5959A (hu)
DZ (1) DZ2714A1 (hu)
GC (1) GC0000096A (hu)
GT (1) GT199900013A (hu)
HK (1) HK1040901B (hu)
HN (1) HN1999000015A (hu)
HU (1) HUP0101268A3 (hu)
IL (2) IL137569A0 (hu)
JO (1) JO2085B1 (hu)
MA (1) MA26600A1 (hu)
MX (1) MXPA00007447A (hu)
NO (1) NO319821B1 (hu)
NZ (1) NZ506597A (hu)
PA (1) PA8467801A1 (hu)
PE (1) PE20000240A1 (hu)
PL (1) PL194350B1 (hu)
SK (1) SK11362000A3 (hu)
TN (1) TNSN99008A1 (hu)
TR (1) TR200002220T2 (hu)
TW (1) TW550069B (hu)
UY (1) UY25374A1 (hu)
WO (1) WO1999038467A1 (hu)
ZA (1) ZA99686B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
WO2001076602A1 (en) * 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
US6762202B2 (en) 2000-05-09 2004-07-13 Nitromed, Inc. Infrared thermography and methods of use
US6737084B2 (en) 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
AU2002235129A1 (en) 2000-11-15 2002-05-27 Tap Pharmaceutical Products Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
CZ20031458A3 (cs) * 2000-11-22 2004-02-18 Abbott Laboratories Léčivo pro léčení sexuální dysfunkce savce
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
CN1720054A (zh) * 2002-03-19 2006-01-11 布雷恩及比扬德生物科技公司 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
CN101227892B (zh) * 2005-04-08 2013-06-05 舌交付有限公司 口腔给药系统
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
EP2233472B1 (en) * 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
DK2442650T3 (en) 2009-06-12 2015-12-07 Cynapsus Therapeutics Inc sublingual apomorphine
WO2011130608A1 (en) * 2010-04-15 2011-10-20 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0641202A1 (en) * 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69534693T2 (de) * 1994-04-22 2006-08-31 Pentech Pharmaceuticals, Inc., Wheeling Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
BG104715A (bg) 2001-02-28
NO20003845D0 (no) 2000-07-27
CN1250221C (zh) 2006-04-12
PL194350B1 (pl) 2007-05-31
PA8467801A1 (es) 2000-09-29
IL137569A (en) 2006-08-01
JP2002501875A (ja) 2002-01-22
NZ506597A (en) 2003-07-25
GC0000096A (en) 2005-06-29
EP1056419A1 (en) 2000-12-06
JO2085B1 (en) 2000-05-21
KR20010040477A (ko) 2001-05-15
NO20003845L (no) 2000-09-28
TW550069B (en) 2003-09-01
CN1313742A (zh) 2001-09-19
US5945117A (en) 1999-08-31
IL137569A0 (en) 2001-07-24
CO4970819A1 (es) 2000-11-07
MA26600A1 (fr) 2004-12-20
ZA99686B (en) 1999-07-28
NO319821B1 (no) 2005-09-19
HK1040901A1 (en) 2002-06-28
EP1056419A4 (en) 2007-05-02
PL342062A1 (en) 2001-05-21
UY25374A1 (es) 1999-09-27
CR5959A (es) 1999-07-28
GT199900013A (es) 2001-07-20
TNSN99008A1 (fr) 2005-11-10
US6193992B1 (en) 2001-02-27
BG64667B1 (bg) 2005-11-30
BR9908038A (pt) 2002-01-02
TR200002220T2 (tr) 2000-12-21
HK1040901B (zh) 2006-11-24
SK11362000A3 (sk) 2001-02-12
DZ2714A1 (fr) 2003-09-01
AU752928B2 (en) 2002-10-03
AU2564499A (en) 1999-08-16
HN1999000015A (es) 1999-08-23
CA2322289A1 (en) 1999-08-05
WO1999038467A1 (en) 1999-08-05
HUP0101268A3 (en) 2002-12-28
AR017976A1 (es) 2001-10-24
MXPA00007447A (es) 2006-01-25
PE20000240A1 (es) 2000-03-31

Similar Documents

Publication Publication Date Title
HUP0101268A2 (hu) A női nemi diszfunkció kezelésére alkalmas gyógyszerkészítmények
DE69803360D1 (de) Anwendungsformen zur behandlung der männlichen erektilen dysfunktion
MY127290A (en) New use of flibanserin
BG104727A (en) Pharmaceutical composition of topiramate
SE9701398D0 (sv) Novel compounds
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MXPA04004966A (es) Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
IL172419A0 (en) Piperazine derivatives and methods of use
ECSP055820A (es) Unidad para dosificación diaria de melatonina
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
EA200000355A2 (ru) Промышленные изделия
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
HUP0400553A2 (hu) Gyógyászati készítmények
BG106155A (en) Novel derivatives and analogues of galanthamin
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
EA200600998A1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
ATE281172T1 (de) Verwendung von cdp-choline zur behandlung des alkoholentzugsyndroms
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
IS6555A (is) Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства